CN111662362B - 一种卡贝缩宫素的纯化方法 - Google Patents
一种卡贝缩宫素的纯化方法 Download PDFInfo
- Publication number
- CN111662362B CN111662362B CN202010759346.5A CN202010759346A CN111662362B CN 111662362 B CN111662362 B CN 111662362B CN 202010759346 A CN202010759346 A CN 202010759346A CN 111662362 B CN111662362 B CN 111662362B
- Authority
- CN
- China
- Prior art keywords
- carbetocin
- solution
- crude product
- phase
- value
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108700021293 carbetocin Proteins 0.000 title claims abstract description 68
- NSTRIRCPWQHTIA-DTRKZRJBSA-N carbetocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSCCCC(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(OC)C=C1 NSTRIRCPWQHTIA-DTRKZRJBSA-N 0.000 title claims abstract description 66
- 229960001118 carbetocin Drugs 0.000 title claims abstract description 66
- 238000000034 method Methods 0.000 title claims abstract description 45
- 239000000243 solution Substances 0.000 claims abstract description 77
- 239000012043 crude product Substances 0.000 claims abstract description 49
- 238000001914 filtration Methods 0.000 claims abstract description 36
- 238000000746 purification Methods 0.000 claims abstract description 36
- 239000008213 purified water Substances 0.000 claims abstract description 16
- 238000004366 reverse phase liquid chromatography Methods 0.000 claims abstract description 15
- 239000007787 solid Substances 0.000 claims abstract description 15
- 239000011259 mixed solution Substances 0.000 claims abstract description 9
- 238000007670 refining Methods 0.000 claims abstract description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 50
- 239000012071 phase Substances 0.000 claims description 34
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 29
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 238000010828 elution Methods 0.000 claims description 12
- 238000004108 freeze drying Methods 0.000 claims description 10
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 8
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 8
- 229920000642 polymer Polymers 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 239000000945 filler Substances 0.000 claims description 5
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims description 4
- 239000005695 Ammonium acetate Substances 0.000 claims description 4
- 229940043376 ammonium acetate Drugs 0.000 claims description 4
- 235000019257 ammonium acetate Nutrition 0.000 claims description 4
- 238000010532 solid phase synthesis reaction Methods 0.000 claims description 4
- 238000007710 freezing Methods 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 2
- 239000007791 liquid phase Substances 0.000 claims description 2
- 238000001308 synthesis method Methods 0.000 claims description 2
- 239000000047 product Substances 0.000 abstract description 7
- 239000012535 impurity Substances 0.000 description 19
- 229960000583 acetic acid Drugs 0.000 description 15
- 238000005185 salting out Methods 0.000 description 13
- 239000000706 filtrate Substances 0.000 description 9
- 239000002244 precipitate Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 210000004291 uterus Anatomy 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 239000003513 alkali Substances 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 230000005526 G1 to G0 transition Effects 0.000 description 4
- 101800000989 Oxytocin Proteins 0.000 description 4
- 102400000050 Oxytocin Human genes 0.000 description 4
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 4
- 229960001723 oxytocin Drugs 0.000 description 4
- 230000001376 precipitating effect Effects 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000018525 Postpartum Hemorrhage Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000004279 Oxytocin receptors Human genes 0.000 description 2
- 108090000876 Oxytocin receptors Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000011097 chromatography purification Methods 0.000 description 2
- 238000010612 desalination reaction Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 229910017053 inorganic salt Inorganic materials 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 206010021118 Hypotonia Diseases 0.000 description 1
- 208000007379 Muscle Hypotonia Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- YCNIBOIOWCTRCL-UHFFFAOYSA-N azane;2,2,2-trifluoroacetic acid Chemical compound [NH4+].[O-]C(=O)C(F)(F)F YCNIBOIOWCTRCL-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001595 contractor effect Effects 0.000 description 1
- 239000012045 crude solution Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003883 substance clean up Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/16—Oxytocins; Vasopressins; Related peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
时间(分钟) | 流动相A(%) | 流动相B(%) |
0 | 85(A1) | 15 |
40 | 85(A1) | 15 |
40.01 | 85(A2) | 15 |
80 | 60(A2) | 40 |
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010759346.5A CN111662362B (zh) | 2020-07-31 | 2020-07-31 | 一种卡贝缩宫素的纯化方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010759346.5A CN111662362B (zh) | 2020-07-31 | 2020-07-31 | 一种卡贝缩宫素的纯化方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111662362A CN111662362A (zh) | 2020-09-15 |
CN111662362B true CN111662362B (zh) | 2021-05-28 |
Family
ID=72393028
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010759346.5A Active CN111662362B (zh) | 2020-07-31 | 2020-07-31 | 一种卡贝缩宫素的纯化方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111662362B (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101531705A (zh) * | 2009-04-21 | 2009-09-16 | 深圳市翰宇药业有限公司 | 一种纯化卡贝缩宫素的方法 |
CN105399799A (zh) * | 2015-12-31 | 2016-03-16 | 郑州大明药物科技有限公司 | 一种卡贝缩宫素的纯化方法 |
CN106478779A (zh) * | 2016-10-24 | 2017-03-08 | 合肥国肽生物科技有限公司 | 一种卡贝缩宫素的制备方法 |
WO2017175233A1 (en) * | 2016-04-04 | 2017-10-12 | Davuluri Ramamohan Rao | Process for large scale liquid phase synthesis of carbetocin and its novel intermediates |
CN109180779A (zh) * | 2018-10-30 | 2019-01-11 | 成都诺和晟泰生物科技有限公司 | 一种纯化制备抗菌肽的方法 |
-
2020
- 2020-07-31 CN CN202010759346.5A patent/CN111662362B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101531705A (zh) * | 2009-04-21 | 2009-09-16 | 深圳市翰宇药业有限公司 | 一种纯化卡贝缩宫素的方法 |
CN105399799A (zh) * | 2015-12-31 | 2016-03-16 | 郑州大明药物科技有限公司 | 一种卡贝缩宫素的纯化方法 |
WO2017175233A1 (en) * | 2016-04-04 | 2017-10-12 | Davuluri Ramamohan Rao | Process for large scale liquid phase synthesis of carbetocin and its novel intermediates |
CN106478779A (zh) * | 2016-10-24 | 2017-03-08 | 合肥国肽生物科技有限公司 | 一种卡贝缩宫素的制备方法 |
CN109180779A (zh) * | 2018-10-30 | 2019-01-11 | 成都诺和晟泰生物科技有限公司 | 一种纯化制备抗菌肽的方法 |
Also Published As
Publication number | Publication date |
---|---|
CN111662362A (zh) | 2020-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110540587B (zh) | 一种有效提高合成肽纯化收率的色谱方法 | |
WO2015062168A1 (zh) | 一种高纯度盐酸万古霉素的分离纯化方法 | |
JP3792777B2 (ja) | 1−アルコキシカルボニル−3−フェニルプロピル誘導体の製造方法 | |
CN101440127B (zh) | 高纯度盐酸万古霉素的制备方法 | |
CN112724241B (zh) | 一种阿巴帕肽的纯化方法 | |
CN112552376B (zh) | 一种纯化维拉卡肽的方法 | |
WO2022156190A1 (zh) | 一种降压肽、长效降压肽及其制备方法 | |
RU2303040C2 (ru) | Очистка пептидов | |
CN114369142B (zh) | 一种纯化醋酸去氨加压素的方法 | |
CN111662362B (zh) | 一种卡贝缩宫素的纯化方法 | |
CN113004373A (zh) | 一种达托霉素的纯化方法 | |
EP1824874B1 (en) | A processs for the purification of crude vancomycin | |
CN109467591B (zh) | 一种西曲瑞克的纯化方法 | |
CN106243214B (zh) | 一种美拉诺坦ⅰ的制备方法 | |
EA004385B1 (ru) | Способ выделения лютеинизирующего гормона | |
CN114409740A (zh) | 一种纯化去氨加压素杂质的方法 | |
CN110845599B (zh) | 一种多肽的制备纯化方法 | |
KR102322423B1 (ko) | 팔미토일 트라이펩타이드-1의 염치환 방법 | |
CN105693844A (zh) | 一种促性腺激素释放激素类似物醋酸盐的制备方法 | |
CN112500407B (zh) | 一种吡咯并喹啉醌二钠盐的纯化方法 | |
CN112250735B (zh) | 一种西曲瑞克的转盐方法 | |
WO2021017793A1 (zh) | 一种化学合成酸性多肽的制备方法 | |
CN111454333B (zh) | 一种高纯度缩宫素的制备方法 | |
CN113683663A (zh) | 一种机体保护多肽粗品的纯化方法 | |
CN109879938B (zh) | 一种醋酸加尼瑞克的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Yuan Yu Inventor after: Li Yuanbo Inventor after: Zuo Cheng Inventor after: Luo Lei Inventor after: Zhao Jianbo Inventor after: Wang Binrong Inventor after: Fu Xiaoping Inventor after: Zhong Guoqing Inventor after: Huang Bo Inventor after: Gao Jian Inventor before: Zuo Cheng Inventor before: Yuan Yu Inventor before: Luo Lei Inventor before: Zhao Jianbo Inventor before: Wang Binrong Inventor before: Fu Xiaoping Inventor before: Zhong Guoqing Inventor before: Huang Bo Inventor before: Gao Jian Inventor before: Li Yuanbo |
|
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: 610000 Chengdu Tianfu International Biological City, Chengdu, Sichuan Province (No. 618 Fenghuang Road, Shuangliu District, Building 6, No. 301, 401, 402) Patentee after: CHENGDU NUOHE SHENGTAI BIOTECHNOLOGY Co.,Ltd. Address before: 610000 Tianfu international bio City, Chengdu, Sichuan, 18 (two section of Bijie Road, Shuangliu District) Patentee before: CHENGDU NUOHE SHENGTAI BIOTECHNOLOGY Co.,Ltd. |